Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
Background HER2 is an actionable target in metastatic colorectal cancer. We assessed the activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.Methods MOUNTAINEER is a global, open-label, phase 2 study that enrolled patients aged 18 years and older with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer at 34 sites (clinics and hospitals) in five countries (Belgium, France, Italy, Spain, and the USA). Initially, the study was designed as a single-cohort study, which was expanded following an interim analysis to include more patients. Initially, patients were given tucatinib (300 mg orally twice daily) plus intravenous trastuzumab (8 mg/kg as an initial loading dose, then 6 mg/kg every 21 days; cohort A) for the duration of treatment (until progression), and after expansion, patients were randomly assigned (4:3), using an interactive web response system and stratified by primary tumour location, to either tucatinib plus trastuzumab (cohort B) or tucatinib monotherapy (cohort C). The primary endpoint was confirmed objective response rate per blinded independent central review (BICR) for cohorts A and B combined and was assessed in patients in the full analysis set (ie, patients with HER2-positive disease who received at least one dose of study treatment). Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT03043313, and is ongoing.Findings Between Aug 8, 2017, and Sept 22, 2021, 117 patients were enrolled (45 in cohort A, 41 in cohort B, and 31 in cohort C), of whom 114 patients had locally assessed HER2-positive disease and received treatment (45 in cohort A, 39 in cohort B, and 30 in cohort C; full analysis set), and 116 patients received at least one dose of study treatment (45 in cohort A, 41 in cohort B, and 30 in cohort C; safety population). In the full analysis set, median age was 56·0 years (IQR 47-64), 66 (58%) were male, 48 (42%) were female, 88 (77%) were White, and six (5%) were Black or African American. As of data cutoff (March 28, 2022), in 84 patients from cohorts A and B in the full analysis set, the confirmed objective response rate per BICR was 38·1% (95% CI 27·7-49·3; three patients had a complete response and 29 had a partial response). In cohorts A and B, the most common adverse event was diarrhoea (55 [64%] of 86), the most common grade 3 or worse adverse event was hypertension (six [7%] of 86), and three (3%) patients had tucatinib-related serious adverse events (acute kidney injury, colitis, and fatigue). In cohort C, the most common adverse event was diarrhoea (ten [33%] of 30), the most common grade 3 or worse adverse events were increased alanine aminotransferase and aspartate aminotransferase (both two [7%]), and one (3%) patient had a tucatinib-related serious adverse event (overdose). No deaths were attributed to adverse events. All deaths in treated patients were due to disease progression.Interpretation Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer.Funding Seagen and Merck & Co.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The HERACLES and MyPathway trials evaluated dual HER2 blockade (trastuzumab in combination with lapatinib or pertuzumab) and the MOUNTAINEER trial assessed trastuzumab in combination with tucatinib, which contributed to the establishment of HER2-targeted therapy as a treatment option in refractory settings [60,61,62].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [62]
In the citing paper
“The objective response rate was 38.1% in patient’s refractory to standard therapy, leading to accelerated FDA approval for patients with the treatment of refractory mCRC.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [70]
Citations
Cites
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citationColon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Self-citationRandomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Self-citationSartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Self-citationBertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Self-citationMeric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
Self-citationNCCN Guidelines Insights: Rectal Cancer, Version 6.2020: Featured Updates to the NCCN Guidelines
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0032 · Cited by 484
Self-citationSiena, S., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00086-3 · Cited by 422
Self-citationAssessment of a HER2 scoring system for colorectal cancer: results from a validation study
Valtorta, E., Martino, C., Sartore-Bianchi, A., Penaullt-Llorca, F., Viale, G., Risio, M., Rugge, M., Grigioni, W., Bencardino, K., Lonardi, S., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.98 · Cited by 313
Self-citation
Research works printed but not linked: 1
- Pheneger, 2009, In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2, Cancer Res, 69
Cited by
Eng, C., Yoshino, T., Ruíz-García, E., Mostafa, N., Cann, C. G., O'Brian, B., Benny, A., Perez, R. O., & Cremolini, C. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00360-x · Cited by 449
Self-citationMosele, M. F., Westphalen, C. B., Stenzinger, A., Barlesi, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 415
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Adam, M., Chang, G., Chen, Y.-J., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0029 · Cited by 371
Self-citationColorectal cancer: Recent advances in management and treatment
Fadlallah, H., El Masri, J., Fakhereddine, H., Youssef, J., Chemaly, C., Doughan, S., & Abou-Kheir, W. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i9.1136 · Cited by 169
“Similarly, Tucatinib is an oral small molecule tyrosine kinase inhibitor that is selective for HER2[128].”
InfluentialHER2-targeted therapies beyond breast cancer — an update
Yoon, J., & Oh, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00924-9 · Cited by 196
“After the protocol amendment, patients were randomized to two additional cohorts allocated either trastuzumab plus tucatinib (cohort B; n = 39) or tucatinib monotherapy (cohort C; n = 30) 5 .”
Metadata
- Authors
- Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., Fountzilas, C., Kardosh, A., Kasi, P. M., Lenz, H.-J., Ciombor, K. K., Elez, E., Bajor, D. L., Cremolini, C., Sanchez, F., Stecher, M., Feng, W., Bekaii-Saab, T. S., Van Cutsem, E., Peeters, M., Van den Evnde, M., André, T., Borg, C., Sarabi, M., Ghiringhelli, F., Chibaudel, B., Siena, S., Cremolini, C., Zampino, M. G., Elez, E., Keranen, S. R., Salazar, R., Alfonso, P., Strickler, J. H., Cercek, A., Ng, K., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., Fountzilas, C., Kardosh, A., Kasi, P. M., Lenz, H.-J., Ciombor, K. K., Bajor, D. L., Bekaii-Saab, T. S., Gbolahan, O., Boland, P., Berg, D., Sanchez, F., Goggins, T., Saeed, A., Burris, H., Bendell, J., Outlaw, D., Tafur, I., Shergill, A., Catenacci, D., Gong, J., Garrido-Laguna, I., Finley, G., Weinberg, B., Shields, A., Philip, P., Turk, A., Nguyen, A., Braiteh, F., Patel, V., Harwin, W., Anderson, I., Kundra, A., Chen, C., Ford, J., Kundranda, M., Nguyen, D., Ratnam, S., Richards, D., Nallapareddy, S., Beeram, S., McKenney, S., & Shao, S.
- Affiliations
- Seagen (United States) (US)
- ORCID
- Feng, Wentao
- Peeters, Marc
- Borg, Christophe
- Sarabi, Matthieu
- Chibaudel, Benoist
- Zampino, Maria G.
- Alfonso, Pilar
- Gbolahan, Olumide
- Boland, Patrick
- Berg, Daniel
- Burris, Howard
- Bendell, Johanna
- Outlaw, Darryl
- Shergill, Ardaman
- Catenacci, Daniel
- Gong, Jun
- Weinberg, Benjamin
- Shields, Anthony
- Turk, Anita
- Braiteh, Fadi
- Chen, Christopher
- Ford, James
- Kundranda, Madappa
- Nguyen, Danny
- Richards, Donald
- Shao, Spencer
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2023-05
- Volume
- 24
- Issue
- 5
- Pages
- 496-508
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4367670315
- Cited by
- 259
- References
- 23
- Citations by year
- 2026: 61 · 2025: 75 · 2024: 100 · 2023: 23
- FWCI
- 31.59
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by-nc-nd)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Merck
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, trastuzumab, HER2-positive colorectal cancer, RAS wild-type, metastatic colorectal cancer, chemotherapy-refractory disease, HER2-targeted therapy, combination therapy, objective response rate, safety, trastuzumab resistance
- MeSH terms
- Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Diarrhea, Female, Humans, Male, Middle Aged, Oxazoles, Pyridines, Quinazolines, Rectal Neoplasms, Cohort Studies, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(23)00150-x
- The paper
- Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., Fountzilas, C., Kardosh, A., Kasi, P. M., Lenz, H.-J., Ciombor, K. K., Elez, E., Bajor, D. L., Cremolini, C., Sanchez, F., . . . Shao, S. (2023). Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(23)00150-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.